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Raul AltmanAbstract
Chronic antithrombotic therapy involves the use of anticoagulants, antiplatelets given either as monotherapy or in
combination for the prevention of thrombotic complications. The most feared and sometimes fatal complication
with this therapy is bleeding. It should be considered a “golden rule” that a drug or combination of drugs that
maximizes efficiency (decreased thromboembolic risk) will probably be less safe (increased risk of bleeding), and
this holds true either for single therapy or during combined therapy. The chances of bleeding indicated by risk
tables can be useful but show only a snapshot, and the biological, social, environmental, and drug changes and
therapeutic adherence also determine changes in the risk of thrombosis and bleeding. Bleeding is an eventuality
that occurs in places of “locus minoris resistentiae,” and the results of careful phase 3 studies thus cannot be
completely predictive of outcomes when a medication is introduced on the pharmaceutical market. With the use of
warfarin, the International Normalized Ratio (INR) that has been established to indicate adequately balanced therapy
is between 2.0 and 3.0. With the new oral anticoagulants, the pharmaceutical companies emphasize that it is not
necessary to monitor anticoagulant effects. In studies with different doses of new oral anticoagulants, however,
incidence of clinically significant bleeding complications have been directly related to the doses. Therefore,
therapeutic excesses can condition bleeding risk and therapeutic limitation can increase thrombotic risk, especially
when short-acting drugs such as the new oral anticoagulants are used. Hence, it is imperative to establish an
appropriate method for monitoring new oral anticoagulants, setting levels of safety and effectiveness through
periodic dosage and monitoring of their anticoagulant effects. Therefore, we still recommend the use of
anticoagulation units for monitoring during treatment with the new oral anticoagulants.
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Chronic antithrombotic therapy involves the use of
anticoagulants, antiplatelets that are given either as
monotherapy or in combination for the prevention of
thrombotic complications. The well-established benefits
of anticoagulant therapy are significantly hampered by
the possibility of major and sometimes fatal bleeding
complications. These adverse effects can range from
simple skin bruising and bleeding bodies in relation to
the outside (epistaxis, gastroduodenal bleeding, pulmon-
ary complications) [1,2] or can affect vital organs with
temporary or permanent impairment of function (intra-
cranial hemorrhage) or death.Correspondence: draltman@arnet.com.ar
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stated.Another risk of even mild bleeding complications is
that they quite frequently lead to the discontinuation of
the anticoagulant therapy, either by the patient or the
physician. The loss of protection by the cessation of the
antithrombotic treatment obviously will favor the devel-
opment of thromboembolic complications [3].
Until very recently, warfarin was the only oral anti-
coagulant medication available, and undoubtedly it was
and still is considered the “gold standard” for the pre-
vention of ischemic stroke in patients with atrial fibrilla-
tion (AF) and/or cardiac valve prosthesis in deep vein
thrombosis and pulmonary embolism. Its efficacy has
been well-established by several large clinical trials com-
paring warfarin versus placebo or antiplatelet agents [4].
This proven efficacy is seriously reduced, however, by
several limitations that affect its wide clinical use [5,6].
Among the major limitations of treatment with vitaminhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
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onset and offset of action, numerous interactions with
food and drugs, and an unpredictable response that re-
quires a systematic monitoring of anticoagulation and
frequent changes in dose.
The increasing aging of the world population may be a
partial explanation for the increase in the rates of AF
diagnosis and other pathological conditions requiring
chronic anticoagulation. These limitations and the in-
crease in numbers of AF patients have triggered an ac-
tive search for better and/or safer anticoagulant drugs.
The new US Food and Drug Administration–approved
oral anticoagulants dabigatran, rivaroxaban, and apixa-
ban are administered as a fixed-oral daily dose to all pa-
tients and seem to share some advantages. In fact, the
new oral anticoagulants work at different levels of the
tissue factor (TF) pathway and could be divided, based
on their mechanism of action, into two major classes: i)
direct thrombin inhibitors (dabigatran) and ii) inhibitors
of the activated coagulation factor X (rivaroxaban and
apixaban).
Dabigatran etexilate is the prodrug of dabigatran that
reversibly inhibits the thrombin active sites of both free
thrombin and thrombin-bound to fibrin. About 80% is
excreted unchanged by the kidney so its administration
is contraindicated in patients with renal failure. Rivarox-
aban is a small molecule with direct inhibitory activity
on activated factor X. It is rapidly absorbed and has a
high bioavailability, is administered once daily, and has a
very short half-life of 5–9 h in healthy volunteers but
that is significantly higher in the elderly (9–13 h). It is
eliminated by the kidneys and liver. Apixaban is a potent
and selective inhibitor of activated factor X with a half-
life of 12 h, 60% bioavailability, and elimination by mul-
tiple routes including via the hepatic metabolism by
cytochrome P450 3A4. In various dose-finding studies
with graded doses of this new oral anticoagulant, the in-
cidence of clinically significant bleeding complications
was directly related to the dose (Table 1) [7-10].
Several major clinical trials have compared the new oral
anticoagulants with warfarin in AF patients (RELY,
ROCKET-AF, and ARISTOTLE) [11-13]. Because of the
better or non-inferior efficacy and lower risk of bleeding
complications combined with fewer interactions with otherTable 1 Bleeding events with new oral anticoagulants in dose
Study drug: endpoint, bleeding
Dabigatran [8] 50 mg × 2
Clinically important % 2.3
Rivaroxaban [9,10] 5 mg
Major after surgery % 2.2
Edoxaban [11] 30 mg
Major + clinically relevant % 3.0drugs and food, the new oral anticoagulants are emerging
as a viable alternative to warfarin for the prevention of
stroke and thromboembolic complications in AF patients.
Therefore, it could be postulated that the new oral an-
ticoagulants, when combined with acetylsalicylic acid
(ASA) or the new PY2 inhibitors in acute coronary syn-
drome patients, may offer some therapeutic benefit over
the traditional warfarin and aspirin. At the same time,
however, it might bring some increases in bleeding com-
plications within the “golden rule” in thrombosis that
those interventions that maximize efficiency (reduction
of events) will probably also increase bleeding risk. It is
therefore necessary to have an idea of the condition of
the patient and to establish the bleeding risk, perhaps
through risk tables. Bleeding is an eventuality that oc-
curs in places of “locus minoris resistentiae,” however,
and the results of careful phase 3 studies thus cannot be
considered fully predictive of “real life” when a medica-
tion enters the pharmaceutical market.
Monotherapy
The use of coumarin as an anticoagulant forced the estab-
lishment of a reference for controlling plasma therapeutic
level. The introduction of International Normalized Ratio
(INR) offered an appropriate method to assess this anti-
coagulant effect. It is widely accepted that the optimal
therapeutic level when using coumarin should be within
INR values of 2.0 and 3.0, or between 2.0 and 3.5 in some
circumstances [14,15]. Lower values will not offer protec-
tion while higher values promote bleeding risk, especially in
individuals of advanced age [16].
Eikelboom et al. used dabigatran in patients with
mechanical heart valves. The initial dabigatran dose (150,
220, or 300 mg twice daily) was based on kidney function
and was adjusted to obtain a trough plasma level of at least
50 ng/ml, but no clotting tests were used to adjust therapy.
The trial was terminated prematurely after the enrollment
of 252 patients because of an excess of thromboembolic
and bleeding events among patients in the dabigatran
group [17].
Combined therapy
Combining two antiplatelet drugs or oral anticoagulant
and one or two antiplatelet drugs produces an increase-finding studies
Daily dose
150 mg × 2 300 mg 225 mg × 2
4.1 4.9 5.1
10 mg 20 mg 30 mg
2.3 4.5 5.4
30 mg × 2 60 60 mg × 2
7.8 3.8 10.6
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that combinations of warfarin, aspirin, or clopidogrel
were associated with an increased risk of fatal and non-
fatal bleeding. In a meta-analysis involving 5938 patients
who had suffered acute coronary syndrome, the addition
of warfarin to aspirin significantly decreased thrombotic
events vs. aspirin alone, but resulted in higher major
bleedings [19]. Another study compared ASA vs ASA +
clopidogrel in warfarin-intolerant patients with AF, and
the combination therapy reduced major ischemic events,
particularly stroke, but at the expense of an increase in
major bleeding (2% per year vs. 1.3% per year; p = 0.001)
[20]. Similar results were obtained in patients with lacu-
nar stroke (SPS3 study); the addition of clopidogrel to
aspirin did not significantly reduce recurrent stroke
but significantly increased the risk of bleeding and mor-
tality [21].
Of importance, in real life, not only the major or
minor bleeding but also skin hemorrhages lead patients
to discontinue therapy and thus increase the potential
risk of thrombosis. Chronic administration of a combin-
ation of antiplatelets has been associated with a high
level of nuisance hemorrhages [22]. Antiplatelet combi-
nations significantly prolong bleeding time and increase
the incidence of subcutaneous hematomas, epistaxis,
hematuria, and severe proctorrhagia [23].
A similar observation seems to apply to the new oral an-
ticoagulants as per the APPRAISE-2 trial. The addition of
apixaban to antiplatelet therapy in high-risk acute coronary
syndrome patients did not significantly reduce ischemic
events but did increase the number of major bleedings, in-
cluding intracranial and fatal hemorrhage [24].
Unfortunately, the need is not uncommon for anti-
platelet (ASA + clopidogrel) and an anticoagulant com-
bination in patients with heart valve prosthesis, AF, and
acute coronary events or coronary stenting. In these
pathological conditions, the theoretical advantage of
thrombotic prevention should be considered against the
risk of bleeding [25,26].
Patients on warfarin undergoing stenting should receive
dual antiplatelet therapy in addition to anticoagulation. This
scenario was studied by Woest et al., who comparedTable 2 Efficacy and bleeding in patients treated with oral an
anticoagulant + clopidogrel + aspirin (triple therapy) (data m
Secondary and safety endpoints at 1 year Double therapeuti
Total efficacy 11.1




Any bleeding event 19.4
NNT: Number need to treat.warfarin + clopidogrel vs. warfarin + clopidogrel + aspirin.
The results showed improved endpoints with the triple
medication but also an increased bleeding that exceeded
efficacy (Table 2) [25].
It has been postulated that in those situations requir-
ing warfarin and dual antiplatelet therapy, the level of
anticoagulation should be lowered to an INR of 2.0–2.5
to reduce bleeding risks without affecting efficacy [27].
This rule cannot be applied to the new oral anticoagu-
lants because of the lack of an effective and reliable clot-
ting assay to measure anticoagulation when using the
new agents.
The benefits of the new oral anticoagulants in acute
coronary syndrome patients receiving antiplatelet ther-
apy were investigated in a meta-analysis of seven pro-
spective studies involving 31,286 patients. The use of
direct thrombin inhibitors or FXa inhibitors was associ-
ated with significant increases in major bleeding that
exceeded the benefits for patients receiving single anti-
platelet therapy [28]. Similar conclusions were reached
in a more recent meta-analysis [29].
Why patients bleed? “The Golden Rule” in antithrombotic
therapy
An abundance of literature supports what we have called
“The Golden Rule” in antithrombotic therapy. Bleeding
charts such as the HAS-BLED have been proposed to
estimate the bleeding risk, including intracranial bleed-
ing in AF patients on anticoagulant therapy with
warfarin [30-34]. The HAS-BLED score includes hyper-
tension, renal conditions, and/or liver disease, history of
stroke, bleeding, the INR lability, age over 65 years, and
alcohol or drug intake [31]. Despite its popularity, the
clinical significance of 7 scoring systems for risk of
bleeding events in patients on anticoagulant therapy was
poor and no better than the subjective evaluation of a
physician [35].
As described before, among the limitations of warfarin,
biological, social, and environmental factors, emerging
medical conditions, and adherence to treatment could
vary and also determine changes in the risk of bleeding.
These variations justify the need for tight medicalticoagulant + clopidogrel (double therapy) or oral
odified from [19])
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different when using the new oral anticoagulants? Be-
cause of their short half-life in combination with the as-
sumption that they do not require routine coagulation
monitoring, patient adherence becomes an extremely
important issue [36].
The full benefit of biologic therapies is not reached and
quality of life is compromised if patients do not adhere to
their medication regimen, and poor adherence is a leading
cause of preventable morbidity and mortality. Among rea-
sons for non-adherence are dislike of taking medications
on a long-term basis and uncertainty about the need for
treatment. The consequences of poor medication adher-
ence contribute to 33 to 69% of hospital admissions in the
United States and cause up to 40% of admissions to US
nursing homes [37]. The use of potentially inappropriate
medications in older people is associated with an increased
risk of adverse drug events and hospitalization [38].
The mostly hepatic metabolization via the cytochrome
P450 pathway seems responsible for the high degree of
interaction with food and other medications of the Vitamin
K antagonists. P-glycoprotein (P-gp) is involved in the
transport of many drugs such as the new oral anticoagu-
lants and is another potential reason for drug interaction.
Therefore, agonists or inhibitors of these pathways could
affect potential drug interactions with these new therapies
[39,40].
The plasma concentration of a new oral anticoagulant
will increase or decrease upon the concomitant presence of
potent P-gp inhibitors or agonists, respectively. In either
case, alterations of new oral anticoagulant pharmacokinet-
ics upon interactions of CYP3A4 or P-gp may complicate
the use of these compounds in daily practice, suggesting
the appropriateness of controlling anticoagulant activity for
improving efficacy and safety.
Dabigatran requires caution when used in combination
with strong inhibitors or inducers of P-gp, such as amioda-
rone or rifampicin. Quinidine used together with dabiga-
tran also is contraindicated. Rivaroxaban (and possibly
apixaban) is contraindicated in combination with drugs that
strongly inhibit both cytochrome P450 3A4 and P-gp, such
as azole antimycotics, and caution is required with its use
in combination with strong inhibitors of only one of these
pathways [41]. Important drug interactions of the new oral
anticoagulants that can lead to adverse clinical reactions
may also occur with non-steroidal anti-inflammatory drugs
and antiplatelet drugs, such as aspirin and clopidogrel.
Clinical experience regarding food interactions is currently
limited [41]. Table 3 shows some drugs that induce P-gp ac-
tivity and P-gp inhibitors that could modify plasma levels of
the new oral anticoagulants and their anticoagulant
activities.
Many drug interactions have shown the involvement
of P-gp and CYP3A4 due to the overlap of substratespecificity and the similarities in their inducers and in-
hibitors. Thus, it can be assumed that the theoretical
possibilities are not fully understood when the new oral
anticoagulants are administered to patients, and control-
ling their anticoagulant effect is necessary or mandatory
or at the least, highly desirable (in acute bleeding, prior
to surgery or invasive procedures, in the possibility of
overdose or subtherapeutic dose, in patients with moder-
ate to severe renal insufficiency or middle or severe hep-
atic damage, for testing drug interaction, in elderly
patient, in obese or very thin patient, or for checking
treatment adherence). This stance is strongly supported
by Bloemen et al. [42], who demonstrated that the
addition of a fixed concentration of any type of anti-
coagulant causes a highly variable inhibition of thrombin
generation in different individuals.
Hemostasis is a local process and occurs normally in mi-
nutes, and thrombin formation is limited [43]. Furie and
Furie mentioned that after injury, the formation of fibrin is
derived from the thrombin generated by the TF exposed
from the vessel wall [44]. The process is circumscribed be-
cause the amount of exposed TF is small in a limited area,
and activators are diluted in the bloodstream in a non-
occluded vessel.
In contrast, arterial thrombosis occurs in areas of ath-
erosclerotic plaque disruption. Atherosclerotic lesion
disruption facilitates the interaction of the circulating
blood with the inner components of the lesions, such as
TF, and this interaction leads to the in vivo generation of
thrombin. The stasis in a partially or fully occluded ves-
sel determines the local increase of thrombin, both free
and bound to fibrin. The flow-limiting effect of the dis-
rupted lesion prevents dilution of the activators and fa-
vors the formation of larger or more stable thrombi.
One of the purposes of antithrombotic therapy is to in-
hibit the pro-thrombotic activity of thrombin, either by
interfering with its synthesis via inhibition of factor Xa (riv-
aroxaban, apixaban) or directly blocking its activity (dabiga-
tran). The relatively small amount of thrombin that is
formed in the case of hemostasis compared with throm-
bosis will be strongly affected by antithrombotic drugs with
impaired hemostasis, and the potential consequence may
be bleeding in a “locus minoris resistentiae” [45]. Although
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lead clinicians to discontinue antithrombotic therapy, which
in turn could increase the risk of myocardial infarction,
stroke, and cardiovascular death. Therefore, therapeutic ex-
cesses can condition bleeding risk, and therapeutic limita-
tion can increase thrombotic risk, especially when short-
acting drugs such as the new oral anticoagulants are used.
Hence, it is imperative to establish an appropriate method
for monitoring new oral anticoagulants and to set the levels
of safety and effectiveness by monitoring their anticoagu-
lant effects.
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